Avoro Capital Advisors Adds $71M in Terns Pharmaceuticals, Inc. ($TERN)
Key Points
- Avoro Capital Advisors changed its Terns Pharmaceuticals, Inc. ($TERN) stake by 30.9% last quarter, boosting to 5,695,000 shares worth $301.55 million.
- Wall Street's consensus rating on $TERN is Hold and an average price target of $53.00.
- $TERN last traded around $52.95.
Avoro Capital Advisors increased its position in Terns Pharmaceuticals, Inc. ($TERN) by 30.9% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,695,000 shares of Terns Pharmaceuticals, Inc. after buying 1,345,000 shares during the quarter. Avoro Capital Advisors's holdings in Terns Pharmaceuticals, Inc. were worth $301.55 million as of its most recent filing.
Terns Pharmaceuticals, Inc. ($TERN) Stock
Terns Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.